A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
BUSINESS
Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
The health ministry’s new guidelines on ethical drug detailing activities took effect this April, requiring drug makers to properly store the daily work reports of their sales reps, and promptly present documents when required by regulatory authorities. Companies are scurrying…
To read the full story
Related Article
- Over 30% of Drug Makers Spot Inappropriate Promotions after Guidelines Enforcement
June 16, 2021
- MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
January 13, 2021
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- Wholesalers Working Out Systems to Comply with Promotion Guidelines, Show Mixed Approaches to External Oversight
October 8, 2019
- New Detailing Guidelines Go into Full Effect on October 1, Making Supervisory Systems Mandatory
October 1, 2019
- New Detailing Guidelines Take Effect on April 1; Q&A on Information Supply on Unapproved Drugs/Indications Issued
April 2, 2019
BUSINESS
- Jardiance’s New Indication Targets Around Half of Chronic Heart Failure Patients: Professor
January 28, 2022
- Yakult Honsha to Launch Velcade Generic in March
January 27, 2022
- Flatiron Health Joins Hands with National Cancer Center to Start Up Japan Biz
January 27, 2022
- Seikagaku Launches New Outpost in Canada
January 27, 2022
- Nippon Shinyaku Sets Up New Sales Firm in Tianjin to Expand Chinese Business
January 27, 2022
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…